472 related articles for article (PubMed ID: 34209213)
21. Involvement and Possible Role of Eosinophils in Asthma Exacerbation.
Nakagome K; Nagata M
Front Immunol; 2018; 9():2220. PubMed ID: 30323811
[TBL] [Abstract][Full Text] [Related]
22. Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy.
Johnsson M; Bove M; Bergquist H; Olsson M; Fornwall S; Hassel K; Wold AE; Wennerås C
J Innate Immun; 2011; 3(6):594-604. PubMed ID: 21921589
[TBL] [Abstract][Full Text] [Related]
23. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma.
Woolley KL; Adelroth E; Woolley MJ; Ellis R; Jordana M; O'Byrne PM
Am J Respir Crit Care Med; 1995 Jun; 151(6):1915-24. PubMed ID: 7767540
[TBL] [Abstract][Full Text] [Related]
24. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
25. Differentiation and functional activity of human eosinophilic cells from an eosinophil HL-60 subline: response to recombinant hematopoietic growth factors.
Fabian I; Lass M; Kletter Y; Golde DW
Blood; 1992 Aug; 80(3):788-94. PubMed ID: 1379088
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways.
Park CS; Choi YS; Ki SY; Moon SH; Jeong SW; Uh ST; Kim YH
Eur Respir J; 1998 Oct; 12(4):872-8. PubMed ID: 9817161
[TBL] [Abstract][Full Text] [Related]
27. IgE and eosinophils as therapeutic targets in asthma.
Patel TR; Sur S
Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
[TBL] [Abstract][Full Text] [Related]
28. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?
Ko E; Chehade M
Clin Rev Allergy Immunol; 2018 Oct; 55(2):205-216. PubMed ID: 29372536
[TBL] [Abstract][Full Text] [Related]
29. Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma.
Choi Y; Le Pham D; Lee DH; Lee SH; Kim SH; Park HS
Exp Mol Med; 2018 Aug; 50(8):1-8. PubMed ID: 30115903
[TBL] [Abstract][Full Text] [Related]
30. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma.
Woolley KL; Adelroth E; Woolley MJ; Ellis R; Jordana M; O'Byrne PM
Eur Respir J; 1994 Sep; 7(9):1576-84. PubMed ID: 7995384
[TBL] [Abstract][Full Text] [Related]
32. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
33. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
34. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.
Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP
Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535
[TBL] [Abstract][Full Text] [Related]
35. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation.
Nixon J; Newbold P; Mustelin T; Anderson GP; Kolbeck R
Pharmacol Ther; 2017 Jan; 169():57-77. PubMed ID: 27773786
[TBL] [Abstract][Full Text] [Related]
37. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
[TBL] [Abstract][Full Text] [Related]
38. IL-5 and IL-5 receptor in asthma.
Kotsimbos AT; Hamid Q
Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():75-91. PubMed ID: 9698919
[TBL] [Abstract][Full Text] [Related]
39. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
40. Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5.
Sonoda Y; Arai N; Ogawa M
Leukemia; 1989 Jan; 3(1):14-8. PubMed ID: 2642572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
